Galecto Inc
(NAS:GLTO)
$
0.6232
-0.0067 (-1.06%)
Market Cap: 16.90 Mil
Enterprise Value: -9.94 Mil
PE Ratio: 0
PB Ratio: 0.60
GF Score: 38/100 Galecto Inc at HC Wainwright Investment Conference - New York Transcript
Sep 11, 2023 / 11:00AM GMT
Release Date Price:
$0.57
(+1.42%)
Boobalan Pachaiyappan
H.C. Wainwright & Co., LLC - Analyst
Hello, everyone. My name is Boobalan Pachaiyappan. I'm H.C. Wainwright Vice President and senior biopharma analyst. With me today is Dr. Hans Schambye, Chief Executive Officer of Galecto.
For investors new to the story, Galecto is a clinical-stage biotech focused on developing novel drugs for fibrosis and cancers. Hans, welcome to the show.
Hans Schambye
Galecto, Inc. - CEO
Thanks a lot, Boobalan. Happy to be here.
Boobalan Pachaiyappan
H.C. Wainwright & Co., LLC - Analyst
Great. So before getting started, I would like to make a disclosure here. I cover Galecto with my colleague, Dr. Ram Selvaraju, who's the Managing Director at the firm. Our recommendation for Galecto is buy rating and $2 price target.
Questions & Answers
Boobalan Pachaiyappan
H.C. Wainwright & Co., LLC - Analyst
Hans, with the formalities out of the way, let's just begin our discussion with IPF program. So
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot